• Privacy policy
  • T&C’s
  • FAQ
  • Meet the Team
  • About The London Economic
  • Advertise
TLE ONLINE SHOP!
NEWSLETTER
SUPPORT THE LONDON ECONOMIC
  • TLE
  • News
  • Politics
  • Opinion
  • Business
  • Sport
  • Entertainment
  • Film
  • Food
  • Lifestyle
  • Property
  • Travel
  • Tech/Auto
No Result
View All Result
The London Economic
  • TLE
  • News
  • Politics
  • Opinion
  • Business
  • Sport
  • Entertainment
  • Film
  • Food
  • Lifestyle
  • Property
  • Travel
  • Tech/Auto
No Result
View All Result
The London Economic
No Result
View All Result
Home Prices and Markets

Sareum Holdings – Potential strategy in COVID-19

RelatedPosts Household savings rise by £20.9 billion despite historically low interest rates Cryptocurrency Exchange CEX.IO Adds New USDT/GBP Trading Pair Ecofin Global Utilities and Infrastructure Trust – Resilient income CQS Natural Resources Growth and Income – Recovery on-hold, hold on The pandemic presents Sareum with an unexpected opportunity to test its lead TYK2 inhibitor, SDC-1801, […]

Edward Marten by Edward Marten
June 26, 2020
in Prices and Markets

RelatedPosts

Household savings rise by £20.9 billion despite historically low interest rates

Cryptocurrency Exchange CEX.IO Adds New USDT/GBP Trading Pair

Ecofin Global Utilities and Infrastructure Trust – Resilient income

CQS Natural Resources Growth and Income – Recovery on-hold, hold on

The pandemic presents Sareum with an unexpected opportunity to test its lead TYK2 inhibitor, SDC-1801, in COVID-19. Such a move would require external funding, but this could accelerate clinical development timelines and catalyse a substantial increase in value for the company. Meanwhile, the recent £1m fundraising allows Sareum to advance SDC-1801 towards trials for mainstream autoimmune conditions… Read more

Sareum intends to make grant applications to explore the activity of SDC-1801 in COVID-19, where the aim would be to reduce the immune system over-reaction that has been seen in the later phase of the infection. If such grant applications are awarded, SDC-1801 could join a group of drugs – including a number of JAK inhibitors – that have been fast-tracked into trials for COVID-19 As a dual TYK2/JAK1 inhibitor, SDC-1801 could be more effective and/or better tolerated than these similar compounds in treating COVID-19.

Meanwhile, Sareum has raised £1m via an equity issue that allows it to advance SDC-1801 into clinical trials for autoimmune disease, consistent with its original business plan.

While QuotedData’s model does not ascribe a value to the COVID-19 opportunity at present, the estimate of the TYK2 assets’ current value has been increased to $30-50m. After modest assumptions for research and development (R&D) spending, QuotedData has assigned a fair value for Sareum in the £25–45m range (0.76–1.38p/share), with the interest in SRA-737 representing upside to the investment case that may be realised in a deal involving the licensee Sierra Oncology.

Read more

NB: Marten & Co was paid to produce this note on Sareum Holdings Plc and it is for information purposes only. It is not intended to encourage the reader to deal in the
security or securities mentioned in this report. Please read the important information at the back of this note. QuotedData is a trading name of Marten & Co Limited which
is authorised and regulated by the FCA. Marten & Co is not permitted to provide investment advice to individual investors categorised as Retail Clients under the rules of
the Financial Conduct Authority.

Support fearless, free, investigative journalism Support fearless, free, investigative journalism Support fearless, free, investigative journalism

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

Trending fromTLE

  • All
  • trending

What If We Got Rid Of Prisons?

Stress, fear and homelessness: The threat looming over families confronted with eviction

File photo dated 07/11/03 of a prison cell.

The Other Prison Pandemic

Latest from TLE

A general view of the City at night from the Southbank in London.

London now has more dollar millionaires than anywhere else

‘This was the deal they demanded’ – dismay as Tory Eurosceptics demand Protocol is ditched

Test and Waste: Serco shareholders in line for juicy dividend on back of Govt contracts

Rumours of ‘Eat Out to Help Out 2’ prompt lively reaction on social media

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

Address

The London Economic Newspaper Limited t/a TLE
Company number 09221879
International House,
24 Holborn Viaduct,
London EC1A 2BN,
United Kingdom

Contact

Editorial enquiries, please contact: jack@thelondoneconomic.com

Commercial enquiries, please contact: advertise@thelondoneconomic.com

SUPPORT

We do not charge or put articles behind a paywall. If you can, please show your appreciation for our free content by donating whatever you think is fair to help keep TLE growing and support real, independent, investigative journalism.

DONATE & SUPPORT

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




No Result
View All Result
  • Home
  • News
  • Politics
  • Opinion
  • Business
  • Sport
  • Entertainment
  • Film
  • Lifestyle
  • Food
  • Property
  • Travel
  • Tech & Auto
  • About The London Economic
  • Meet the Team
  • Privacy policy

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.